Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 104 entries
View as:

Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy

Phase: N/A Priority: Normal
NCT ID: NCT06369272 Org: User:
Start: 03/01/23 End: 10/20/23 Due: 10/20/24

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Phase: N/A Priority: Normal
NCT ID: NCT04917861 Org: User:
Start: 06/08/21 End: 07/26/24 Due: 07/26/25

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Phase: N/A Priority: Normal
NCT ID: NCT04144348 Org: User:
Start: 11/04/19 End: 12/20/22 Due: 12/20/23

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Phase: N/A Priority: Normal
NCT ID: NCT03897881 Org: User:
Start: 07/18/19 End: 09/09/29 Due: 09/09/30

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT05659264 Org: User:
Start: 12/05/22 End: 12/17/24 Due: 12/17/25

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

Phase: N/A Priority: Normal
NCT ID: NCT06147856 Org: User:
Start: 03/29/24 End: 08/05/27 Due: 08/05/28

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

Phase: N/A Priority: Normal
NCT ID: NCT04528719 Org: User:
Start: 09/30/20 End: 07/18/24 Due: 07/18/25

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

Phase: N/A Priority: Normal
NCT ID: NCT06189053 Org: User:
Start: 04/30/22 End: 10/31/28 Due: 10/31/29

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05894499 Org: User:
Start: 11/15/22 End: 05/26/23 Due: 05/26/24

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03392389 Org: User:
Start: 12/04/17 End: 07/29/19 Due: 07/29/20

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05827068 Org: User:
Start: 03/27/23 End: 11/20/23 Due: 11/20/24

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03323398 Org: User:
Start: 08/15/17 End: 08/18/21 Due: 08/18/22

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Phase: N/A Priority: Normal
NCT ID: NCT05683457 Org: User:
Start: 04/05/23 End: 08/01/26 Due: 08/01/27

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03345043 Org: User:
Start: 05/11/16 End: 08/13/18 Due: 08/13/19

A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in Adults to Prevent COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT06585241 Org: User:
Start: 09/09/24 End: 10/29/25 Due: 10/29/26

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Phase: N/A Priority: Normal
NCT ID: NCT05572658 Org: User:
Start: 09/15/22 End: 09/30/23 Due: 09/30/24

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05831111 Org: User:
Start: 04/05/23 End: 06/24/27 Due: 06/24/28

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Phase: N/A Priority: Normal
NCT ID: NCT06067230 Org: User:
Start: 10/06/23 End: 07/30/26 Due: 07/30/27

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT06634797 Org: User:
Start: 10/08/24 End: 01/20/25 Due: 01/20/26

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase: N/A Priority: Normal
NCT ID: NCT04899310 Org: User:
Start: 08/06/21 End: 08/01/28 Due: 08/01/29

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

Phase: N/A Priority: Normal
NCT ID: NCT06354998 Org: User:
Start: 04/08/24 End: 05/10/24 Due: 05/10/25

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

Phase: N/A Priority: Normal
NCT ID: NCT06592794 Org: User:
Start: 09/24/24 End: 05/31/27 Due: 05/31/28

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04916431 Org: User:
Start: 07/28/21 End: 08/02/22 Due: 08/02/23

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Phase: N/A Priority: Normal
NCT ID: NCT05295433 Org: User:
Start: 03/08/22 End: 04/02/34 Due: 04/02/35

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

Phase: N/A Priority: Normal
NCT ID: NCT06333704 Org: User:
Start: 03/10/23 End: 12/10/28 Due: 12/10/29